Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases

Hepatitis B virus (HBV) remains a major global public health problem worldwide; in endemic areas, mother-to-child transmission (MTCT) of HBV is the most common transmission route. Previous studies have shown that amniocentesis for prenatal diagnosis increases the risk of MTCT of HBV among highly vir...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases 2021-07, Vol.21 (1), p.1-716, Article 716
Main Authors: Han, Zhenyan, Zhang, Yuan, Zhou, Jin, Wang, Qingqing, Huang, Yonghua, Hou, Hongying
Format: Article
Language:English
Subjects:
Amniocentesis
Antigen presentation
Antigens
Antiviral agents
Babies
Blood
Case Report
Case studies
Childbirth & labor
Children
Diagnosis
Diagnostic tests
Fetal blood
Fetal blood sampling
Fetuses
Health aspects
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B surface antigen
Infections
Medical examination
Mother-to-child transmission
Mothers
Perinatal infection
Pregnancy
Prenatal diagnosis
Public health
Risk
Risk factors
Sampling
Serology
Therapy
Ultrasonic imaging
Umbilical cord
Vaccines
Viruses
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B virus (HBV) remains a major global public health problem worldwide; in endemic areas, mother-to-child transmission (MTCT) of HBV is the most common transmission route. Previous studies have shown that amniocentesis for prenatal diagnosis increases the risk of MTCT of HBV among highly viraemic mothers. However, no data is available on MTCT related fetal blood sampling (FBS) because of the paucity of cases or lack of attention. We present a case series of HBV-infected women who underwent FBS with or without antiviral therapy during pregnancy and discuss the risk of MTCT after FBS. FBS may increase the risk of MTCT of HBV in women with HBeAg-positive and high viral loads; therefore, FBS should be avoided in this high-risk population. Maternal HBV serologic testing and awareness of the potential risk of MTCT should be recommended before FBS. Antiviral therapy may be effective to decrease the risk of MTCT after FBS in highly viraemic women.
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-021-06423-x